More about

Adalimumab

News
June 20, 2022
2 min read
Save

‘Surprisingly high’ remission rates for both ustekinumab, adalimumab in Crohn’s patients

Ustekinumab and adalimumab demonstrated equally high rates of clinical remission in biologic-naïve patients with moderate to severe Crohn’s disease through 1 year of treatment, according to results of the SEAVUE study in The Lancet.

News
May 11, 2022
1 min read
Save

Ixekizumab bests adalimumab in adherence, persistence in psoriasis

Ixekizumab bests adalimumab in adherence, persistence in psoriasis

Patients with psoriasis who were treated with ixekizumab were more likely to adhere to therapy compared with those treated with adalimumab over a 24-month period, according to a study.

News
April 21, 2022
3 min read
Save

Upcoming biosimilar logjam could provide cost savings for arthritis drugs

Upcoming biosimilar logjam could provide cost savings for arthritis drugs

The upcoming influx of new biosimilar drugs to the market could mitigate the cost of biologics to treat inflammatory diseases, said Steven Newmark, director of policy and chief legal officer for the Global Healthy Living Foundation.

News
April 20, 2022
15 min watch
Save

VIDEO: Hidradenitis suppurativa patient experience, management, care ‘key themes’ at meeting

VIDEO: Hidradenitis suppurativa patient experience, management, care ‘key themes’ at meeting

In this video, Haley Naik, MD, discusses “three key themes” from the hidradenitis suppurativa symposiums at the American Academy of Dermatology Annual Meeting.

News
March 14, 2022
3 min read
Save

Tofacitinib exhibits shorter timeline to initial clinical response in PsA vs. placebo

Tofacitinib exhibits shorter timeline to initial clinical response in PsA vs. placebo

Tofacitinib for psoriatic arthritis is efficacious in most patient-reported and clinical endpoints over time, and shows shorter initial and meaningful response times versus switching from placebo to the drug at month 3, noted researchers.

News
February 10, 2022
2 min read
Save

TNF inhibitor use in juvenile idiopathic arthritis triples risk for psoriasis

TNF inhibitor use in juvenile idiopathic arthritis triples risk for psoriasis

Exposure to TNF inhibitors nearly triples the risk for psoriasis among children with juvenile idiopathic arthritis, according to data published in the Annals of the Rheumatic Diseases.

News
January 31, 2022
3 min read
Save

Norway 'excellent example' of how to increase access to biosimilars

Norway 'excellent example' of how to increase access to biosimilars

The European Union, and specifically Norway, has demonstrated successful strategies for making biosimilars available for patients — and realizing “tremendous savings” — that should be adopted in the United States, according to an analysis.

News
January 20, 2022
2 min read
Save

Biosimilar, originator DMARDs exhibit no differences in treatment retention

Biosimilar, originator DMARDs exhibit no differences in treatment retention

There are no clinically relevant differences in treatment retention among patients receiving biosimilar or originator biologic disease-modifying antirheumatic drugs as first exposure to that drug, data published in Rheumatology show.

News
January 14, 2022
1 min read
Save

Top in rheumatology: Inflammatory disease biosimilars, depression in patients with lupus

Top in rheumatology: Inflammatory disease biosimilars, depression in patients with lupus

In October, Boehringer Ingelheim’s Cyltezo was approved by the FDA as the first interchangeable biosimilar to AbbVie’s Humira.

News
January 12, 2022
2 min read
Save

Intensive drug therapy improves stricture-associated inflammation in CD

Intensive drug therapy improves stricture-associated inflammation in CD

Intensive drug therapy improved symptoms, stricture-associated inflammation and stricture morphology among patients with Crohn’s disease, according to research published in The Lancet Gastroenterology & Hepatology.

View more